Children with microcephaly and non-Hodgkin's lymphoma (NHL) The data of our nine patients are shown in the table. Familial microcephaly was seen in two patients. In three families other congenital malformations were found, and immunodeficiency was confirmed in six patients.
The outcome of treatment was not affected by the presence of microcephaly,6 despite treatment modifications to reduce toxicity (including omission of alkylating agents and/or irradiation of the central nervous system). Unfortunately, we were unable to perform complete immunological and cytogenetical examinations in our patients. However, there are reasons to believe that most of our cases were truly children with Seemanova's syndrome. It will be necessary to study more children to help explain the relation between congenital malformations, immunodeficiency, and malignancy. Ocular relapse in acute lymphoblastic leukaemia EDITOR,-Ocular relapse associated with acute lymphoblastic leukaemia (ALL) is rarely seen nowadays as a result of improved treatment of childhood leukaemia. A 12 year old boy with ALL was treated in accordance with the recent UKALL protocol which did not include cranial irradiation. He developed leukaemic infiltration of his left eye while in remission and on maintenance chemotherapy, seven months after the original diagnosis. Lumbar puncture revealed central nervous system (CNS) relapse and he underwent local irradiation to the left orbit with a maximum dose of 800 cGy and subsequently reinduction chemotherapy and craniospinal irradiation. After initial partial resolution of signs, infiltrates persisted and 10 weeks later he underwent further craniospinal irradiation with 2400 cGy applied to the right and left cranium in 15 fractions with 6 MV x rays, resulting in a gradual improvement over a three month period and he remained in remission.
By six months only residual pigmentary changes were observed in the fundus and maintenance treatment was stopped due to neutropenia with the CNS remaining clear of blast cells. However, two weeks later, he developed further ocular recurrence which temporarily resolved on treatment, and subsequently further ocular and CNS relapse, and died 11 months after his original ocular presentation.
Ocular involvement in leukaemia is most commonly a consequence of associated haematological abnormalities and usually occurs when the patient is in relapse. Anaemia may precipitate a leukaemic retinopathy and hyperviscosity may give rise to microaneurysms, capillary closure, and retinal neovascularisation. Less frequently direct invasion of leukaemic cells may lead to ocular infiltration which carries a poor prognosis and is associated with CNS relapse. ' A recent study revealed 96% of children with ALL died within 28 months of onset of ocular signs. Of those patients with ocular manifestations in ALL, 82% had CNS leukaemia.2 It has been shown that intrathecal methotrexate does not reach the eye, and its effect on tumour cells in the optic nerve is demonstrable only as far as the termination of the subdural space posterior to the globe.3
A multicentre study of leukaemic ophthalmopathy suggests that those leukaemic patients with ocular involvement, in first4 complete remission, may be cured with chemotherapy and high dose radiotherapy to the affected eye,4 and it is still possible to achieve remission after a second ocular relapse. If the eye is the sole sanctuary site, then enucleation may be indicated. Lo Curto and associates presented a case of isolated ocular relapse in which enucleation was undertaken after a third ocular relapse. The eye had previously been treated with chemotherapy and radiotherapy with a dose of 390 cGy at first relapse and 20 Gy at the second. The patient remained well 11 years after enucleation. It has been proposed that a dose of 20 Gy may be ineffective against ocular leukaemia, and that higher doses of over 30 Gy may be necessary to eradicate ocular leukaemic cells.4
Although ocular sanctuary is a well known but very rare form of relapse, its occurrence is associated with an extremely poor prognosis and high dose radiotherapy should be urgently instituted. As routine cranial irradiation is no longer mandatory for standard risk cases, it is important that such cases presenting with ocular relapse should be thoroughly assessed to ensure adequate evaluation of current treatment protocols. The selection of donor mothers was considered very carefully and the guidelines emphasise the need to screen for HIV, syphilis, HTLV I and HI, and hepatitis B and C. The published guidelines include a sample information sheet about screening for infectious diseases and sample instructions for the expression ofmilk and the personal hygiene of donors. Detailed guidance is given on all milk banking procedures including microbiological screening and pasteurisation. A minimum exposure of 57°C for 30 minutes or a maximum of 63°C for 30 minutes is recommended and the importance of rigorous quality control stressed. Common questions about temperature and length of storage are answered and recommendations made for the handling and thawing of frozen pasteurised breast milk. Standards for documentation are provided to permit tracing of a donor, if necessary.
Established milk banks and those in the process of being set up will find this document valuable. It draws together evidence from 41 papers. The working party feel that it would be helpful if there was uniformity of practice throughout the UK and these guidelines might promote this. The clinical benefits demonstrated in the paper, especially reduction in breakthrough wheezing and avoidance of repeated hospitalisations, would lead to significant savings on scarce resources, even in the public sector.
In the Sri Lankan non-fee levying public sector, till very recently, the management of these severe asthmatics revolved round the use of oral ,3 agonists, oral theophyllines, and intermittent systemic steroids. However, I am pleased to report that on the basis of the work presented, the Sri Lankan Ministry of Health has agreed in principle to provide inhaled steroids through the paediatricians of the national health service. Presently, at Lady Ridgeway Hospital, we are able to prescribe these drugs to needy children, completely free of charge. This has resulted in a marked reduction in admissions for acute severe asthma.
The costs calculated were those that were incurred by the patients, inclusive of costs of hospitalisation, travelling, consultations, drugs, etc for the first year on treatment. The cost per consultation was Rs 125.00 (, Cl.55 
